Evidence map›Paper›PMID 33841412›Full record

Observational studyFrontiers in immunology2021

Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients From South Africa.

Kimesha Pillay, Lara Lewis, Santhuri Rambaran, Nonhlanhla Yende-Zuma, Derseree Archary, Santhanalakshmi Gengiah, Dhineshree Govender, Razia Hassan-Moosa, Natasha Samsunder, Salim S Abdool Karim and 4 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Heightened Microbial Translocation Is a Prognostic Biomarker of Recurrent Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Kimesha PillayCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Lara LewisCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Santhuri RambaranCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Nonhlanhla Yende-ZumaCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Derseree ArcharyCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Santhanalakshmi GengiahCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Dhineshree GovenderCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Razia Hassan-MoosaCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Natasha SamsunderCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Salim S Abdool KarimCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Lyle R McKinnonCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Nesri PadayatchiCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Kogieleum NaidooCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Aida SivroCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Centre for the AIDS Programme of Research in South Africa · ZAUniversity of KwaZulu-Natal · ZAColumbia University · USUniversity of Manitoba · CA

Funding

CDC HHS UY2G/PS001350Howard Hughes Medical Institute 55007065
6 · The paper itself

Abstract

There is an urgent need to identify immunological markers of tuberculosis (TB) risk in HIV co-infected individuals. Previously we have shown that TB recurrence in HIV co-infected individuals on ART was associated with markers of systemic inflammation (IL-6, IL1β and IL-1Rα). Here we examined the effect of additional acute inflammation and microbial translocation marker expression on risk of TB recurrence. Stored plasma samples were drawn from the TB Recurrence upon Treatment with HAART (TRuTH) study, in which individuals with previously treated pulmonary TB were screened for recurrence quarterly for up to 4 years. Recurrent TB cases (n = 37) were matched to controls (n = 102) by original trial study arm assignment and ART start date. Additional subsets of HIV infected (n = 41) and HIV uninfected (n = 37) individuals from Improving Recurrence Success (IMPRESS) study were sampled at active TB and post successful treatment completion. Plasma concentrations of soluble adhesion molecules (sMAdCAM, sICAM and sVCAM), lipopolysaccharide binding protein (LBP) and transforming growth factor-beta (TGF-β1, TGF-β2, TGF-β3) were measured by multiplex immunoassays and ELISA. Cytokine data was square root transformed in order to reduce variability. Multivariable analysis adjusted for a number of potential confounders measured at sample time-point: age, BMI, CD4 count, viral load (VL) and measured at baseline: presence or absence of lung cavities, previous history of TB, and WHO disease stage (4 vs 3). The following analytes were associated with increased risk of TB recurrence in the multivariable model: sICAM (aOR 1.06, 95% CI: 1.02-1.12, p = 0.009), LBP (aOR 8.78, 95% CI: 1.23-62.66, p = 0.030) and TGF-β3 (aOR 1.44, 95% CI 1.01-2.05, p = 0.044). Additionally, we observed a positive correlation between LBP and sICAM (r= 0.347, p<0.0001), and LBP and IL-6, identified to be one of the strongest predictors of TB risk in our previous study (r=0.623, p=0.03). These data show that increased risk of TB recurrence in HIV infected individuals on ART is likely associated with HIV mediated translocation of microbial products and the resulting chronic immune activation.

Indexed as

Acute-Phase ProteinsAdultAntiretroviral Therapy, Highly ActiveBacterial TranslocationBiomarkersCarrier ProteinsCD4 Lymphocyte CountCohort StudiesCytokinesFemaleHIV InfectionsHumansLipopolysaccharide-Binding ProteinMaleMembrane GlycoproteinsRecurrenceAcute-Phase ProteinsBiomarkersCarrier ProteinsCytokinesLipopolysaccharide-Binding ProteinMembrane GlycoproteinsTransforming Growth Factor betaantiretroviral (ARV) therapyHIVinflammationmicrobial translocationtuberculosis - pulmonary

Identifiers

PMID33841412
PMCPMC8026888
OpenAlexW3151988918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.